ArticleFrontiers in medicine2026
Proteomic analysis of corneal astigmatism identifies reduced apolipoprotein A-IV as a candidate biomarker.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Astigmatism is a common refractive error associated with myopia, yet its molecular mechanisms remain poorly understood. This study aimed to identify and validate differentially expressed proteins (DEPs) in corneal astigmatism through a label-free quantitative proteomic approach, followed by biomarker validation using parallel reaction monitoring (PRM). Methods: This two-phase, retrospective case-control study aimed to identify and verify differentially expressed proteins (DEPs) associated with corneal astigmatism. Phase I (discovery) employed label-free quantitative (LFQ) proteomics to compare stromal samples from 9 patients (10 eyes) with compound myopic astigmatism (Group A) and 8 patients (10 eyes) with simple myopia (Group B). Phase II (verification) involved targeted parallel reaction monitoring (PRM) in an independent cohort comprising 13 patients (15 eyes) in Group A and 14 patients (15 eyes) in Group B, quantifying discovery-prioritized proteins. Bioinformatic analyses including COG, GO, KEGG, and protein-protein interaction mapping were performed to characterize enriched pathways and guide PRM target selection. Results: A total of 127 DEPs were identified, with 31 upregulated and 96 downregulated in Group A. Bioinformatic analysis of the discovery dataset showed enrichment of proteins associated with wound healing, blood coagulation, and lipid metabolism; these enrichments were exploratory and were used only to prioritize candidates for targeted verification. Targeted PRM verified a significant reduction in APOA4 in astigmatism; other candidates showed concordant trends without statistical significance. Conclusion: After targeted verification, APOA4 was the only protein that remained significantly reduced in corneal astigmatism, supporting reduced APOA4 as a candidate biomarker that warrants further study. The discovery-phase associations with coagulation, lipid metabolism, and wound-healing pathways were not confirmed at the protein level and should be regarded as hypothesis-generating, requiring confirmation in larger, adequately powered cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.